驶入新航道下一站！劲方医药（2595.HK）在香港联交所主板挂牌上市

Core Viewpoint - Jinfang Pharmaceutical (2595.HK) officially listed on the Hong Kong Stock Exchange on September 19, raising a total of $268 million, marking the largest fundraising in the Hong Kong 18A sector since 2022 [1][3] Company Overview - Jinfang Pharmaceutical is a globally positioned innovative drug development company focusing on unmet clinical needs in oncology and immune-related diseases, leveraging disease biology mechanisms and clinical translational medicine [6] - The company has established a comprehensive R&D system with multiple proprietary "global new" projects, entering global multi-center clinical trials in China, Europe, and the United States since its establishment in 2017 [6] IPO Details - The IPO raised $233 million before the exercise of the over-allotment option, which increased the total to $268 million, with cornerstone investors contributing $100 million [1][3] - The company was exclusively sponsored by CITIC Securities for this IPO [1] Product Pipeline - The company’s first approved product, Daberu (Fluorazeres), is the first KRAS G12C inhibitor approved in China and the third globally, with a comprehensive RAS-targeted therapy matrix developed [3][6] - Jinfang has completed the development of multiple selective and pan-RAS inhibitors, with several products leading in development speed both domestically and internationally [4][6] Clinical Research and Innovations - The company is advancing multiple original products, including GFH375, an oral KRAS G12D inhibitor, which is in the first tier of development for treating pancreatic cancer and non-small cell lung cancer [4] - The KROCUS study is the first global trial for KRAS+EGFR first-line treatment of non-small cell lung cancer, while GFS202A is the first clinical-stage dual antibody therapy for cachexia [5] Strategic Partnerships and Collaborations - Since 2021, Jinfang has engaged in licensing agreements with several domestic and international companies, including Innovent Biologics and Verastem Oncology, enhancing its commercial collaboration network [3][6] - The company has received various national and local recognitions, including being named a "Little Giant" enterprise and a high-tech enterprise, reflecting its innovation and growth potential [6]